Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...

French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...

The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary ...

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune thrombocytopenia (ITP) in the adult population, met its primary endpoint.

Let’s roll. An oral treatment developed by the French pharma giant Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder that causes the body ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).